OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

CurrentAetnaPolicy 0315

Etanercept (Enbrel) — Coverage Criteria and Prior Authorization

Customize your policy alerts

Sign up for Aetna Policy 0315 alerts

Get alerted when Policy 0315 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Clinical coverage and prior authorization requirements for etanercept (Enbrel) including indications, prescriber specialty requirements, initial and continuation criteria, dosing notes, and experimental/investigational exclusions for Aetna members.

Policy Summary

PayerAetna

PolicyEtanercept (Enbrel) — Coverage Criteria and Prior Authorization

Policy CodePolicy 0315

Change TypeNo material change

Effective DateFeb 10, 1999

Last ReviewFeb 15, 2024

Next Review DateOct 24, 2024

Key ActionObtain prior authorization and document a negative TB test within 6 months and required prescriber specialty or consultation.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

7+FDA indications

46%PASI-75 (adult)

57%Pediatric PASI-75

YesBlack-box warnings

ErelziBiosimilar mentioned

02/10/1999Original effective

Coverage Criteria for Etanercept (Enbrel)

Initial Approval - Indication-specific criteria

Covered when the listed indication‑specific selection criteria are met and the member has a documented negative tuberculosis (TB) test within 6 months prior to initiation (PPD, IGRA, or chest x‑ray); prescriber specialty requirements apply.

General requirements: Member has a documented negative TB test (PPD, IGRA, or chest x‑ray) within 6 months prior to initiation, or latent TB has been treated prior to starting etanercept; prescriber is of required specialty or in consultation per indication; dosing limits follow FDA/labeling.

If TB test positive, evaluate to exclude active disease and treat latent TB before initiating etanercept; do not start during active infection.

Rheumatoid arthritis (adults): Either member previously received a biologic or targeted synthetic drug indicated for moderately to severely active RA; OR all of the following: (1) member has a positive RF or anti‑CCP test OR has had testing for RF, anti‑CCP and CRP/ESR; AND (2) inadequate response to at least a 3‑month trial of methotrexate titrated to >=15 mg/week, or intolerance/contraindication to methotrexate.

Per RA initial criteria in policy.

Policy Summary

PayerAetna

PolicyEtanercept (Enbrel) — Coverage Criteria and Prior Authorization

Policy CodePolicy 0315

Change TypeNo material change

Effective DateFeb 10, 1999

Last ReviewFeb 15, 2024

Next Review DateOct 24, 2024

Key ActionObtain prior authorization and document a negative TB test within 6 months and required prescriber specialty or consultation.

SourceLink

On This Page

Articular juvenile idiopathic arthritis (>=2 years): Either previously received a biologic/targeted synthetic indicated for articular JIA; OR any of: inadequate response to methotrexate or another conventional synthetic DMARD at adequate dose/duration; OR inadequate response to scheduled NSAIDs and/or intra‑articular glucocorticoids plus one of listed poor‑outcome risk factors (e.g., ankle, wrist, hip, sacroiliac, TMJ involvement; erosive disease; delay in diagnosis; elevated inflammation markers; symmetric disease); OR presence of risk factors for severe/refractory course plus one additional severity criterion.

Age and appendix B risk factors per policy.

Psoriatic arthritis (>=2 years): Either previously received a biologic/targeted synthetic indicated for PsA; OR either: mild–moderate disease with inadequate response to methotrexate, leflunomide, or another conventional synthetic DMARD at adequate dose/duration or intolerance/contraindication; or severe disease.

PsA initial criteria per policy.

Ankylosing spondylitis/axial spondyloarthritis (adults): Either previously received a biologic/targeted synthetic indicated for AS/axSpA; OR any of: inadequate response to at least two NSAIDs, or intolerance/contraindication to two or more NSAIDs.

AxSpA/AS initial criteria per policy.

Plaque psoriasis (>=4 years): Either previously received a biologic indicated for moderate‑to‑severe plaque psoriasis; OR any of: involvement of crucial body areas (hands, feet, face, neck, scalp, genitals/groin, intertriginous areas); OR >=10% BSA affected; OR >=3% BSA plus inadequate response/intolerance to phototherapy or systemic agents (methotrexate, cyclosporine, acitretin) or clinical reason to avoid them.

Pediatric age thresholds and weight‑based dosing referenced elsewhere in policy.

Reactive arthritis: Either previously received a biologic indicated for reactive arthritis; OR inadequate response to methotrexate or sulfasalazine; OR intolerance/contraindication to methotrexate and sulfasalazine.

Reactive arthritis initial criteria per policy.

Hidradenitis suppurativa (severe, refractory): Either previously received a biologic indicated for severe refractory HS; OR inadequate response to an oral antibiotic regimen for >=90 days; OR intolerance/contraindication to oral antibiotics used for HS.

HS initial criteria per policy.

Behçet's disease: Either previously received apremilast or a biologic indicated for Behçet's; OR inadequate response to at least one non‑biologic medication for Behçet's disease (e.g., azathioprine, colchicine, cyclosporine, systemic corticosteroids).

Behçet’s initial criteria per policy.

Immune checkpoint inhibitor‑related toxicity / severe ICI‑related inflammatory arthritis: For SJS/TEN due to ICI‑related toxicity OR severe ICI‑related inflammatory arthritis: member has had an inadequate response to corticosteroids or a conventional synthetic drug, or has intolerance/contraindication to these therapies.

Policy lists ICI‑related indications and failure/intolerance criteria.

Experimental/Investigational exclusions: Concomitant use of etanercept with any other biologic or targeted synthetic drug for the same indication is considered experimental/investigational. Other indications listed in the Experimental and Investigational section are not supported for routine coverage.

See Experimental and Investigational list in policy.

Continuation of Therapy

Covered when the member achieves or maintains a positive clinical response on etanercept for the approved indication.

General continuation requirement: Member meets all initial selection criteria and demonstrates clinical improvement or low disease activity as specified for the condition.

Examples of specific measures: >=20% improvement in tender/swollen joint counts for RA; improvement in joint counts, function, pain, BSA, abscess/nodule counts, or disease‑specific validated measures from baseline per indication.

RA continuation measures: Improvement of at least 20% from baseline in tender joint count, swollen joint count, pain, or disability.>=20% improvement

Continuation requires documented clinical response per RA criteria.

JIA continuation measures: Demonstrated low disease activity or improvement in any of: number of joints with active arthritis, number of joints with limitation of movement, or functional ability compared with baseline.

Applies to members >=2 years using etanercept for articular JIA.

PsA continuation measures: Improvement in any of: number of swollen joints, number of tender joints, dactylitis, enthesitis, axial disease, or skin/nail involvement from baseline.

Applies to members >=2 years for PsA.

AS/axSpA continuation measures: Improvement in any of: functional status, total spinal pain, or inflammation (e.g., morning stiffness) from baseline.

Applies to adult members with AS/axSpA.

Plaque psoriasis continuation measures: Either reduction in BSA affected from baseline or improvement in signs/symptoms (e.g., itching, redness, flaking, scaling, burning, cracking, pain).

Applies to members >=4 years.

Hidradenitis suppurativa continuation measures: Improvement in any of: reduction in abscess/inflammatory nodule count, reduced formation of new sinus tracts/scarring, decreased frequency of inflammatory lesions, reduction in pain or suppuration, or improved quality of life/disease severity score from baseline.

Applies to severe, refractory HS.

Indications and safety considerations

Covered for FDA‑approved indications and considered for listed compendial uses when supported by clinical rationale and documentation; safety screening and monitoring are required.

Approval prerequisites: Patient has a documented indication that matches an FDA‑approved use (RA, pJIA >=2 years, PsA, AS, plaque psoriasis >=4 years, JPsA) or a documented compendial (off‑label) indication supported by clinical rationale and documentation.

See FDA‑approved indications and compendial uses in policy.

Safety requirements: Document latent TB testing (PPD or IGRA or chest x‑ray) prior to initiation; if latent TB positive, start TB therapy prior to initiating etanercept; do not start during active infection; monitor for active TB and other serious infections during therapy.TB test within 6 months prior to start

Black‑box warnings require this screening and monitoring.

Contraindications / precautions to document: Document history of demyelinating disease, congestive heart failure worsening or new onset, active severe infection, prior malignancy (including pediatric lymphoma reports), hepatitis B history, or other labeled precautions when assessing appropriateness.

Labeled warnings and precautions should inform risk assessment.

Evidence summaries by indication and biosimilar

Summaries of key evidence supporting indicated uses and biosimilar data to inform coverage decisions.

Erelzi (etanercept‑szzs) FDA indications: Erelzi is FDA‑approved for active ankylosing spondylitis, active psoriatic arthritis (including use with methotrexate), chronic moderate‑to‑severe plaque psoriasis in adults, moderate‑to‑severe polyarticular JIA (>=2 years), and moderate‑to‑severe rheumatoid arthritis (alone or with MTX).

FDA approval summary for biosimilar.

Biosimilar randomized trial evidence (LBEC0101): A 54‑week phase‑III randomized study in RA (n=374) showed DAS28‑ESR change at week 24 within equivalence margins and similar ACR20 rates between biosimilar and reference etanercept; comparable AEs and lower ADA rates were observed with the biosimilar.

Matsumo et al. phase‑III trial evidence.

Real‑world SB4 (Benepali) evidence: Systematic review of real‑world SB4 use across 9 European countries reported 13,552 patients with similar disease activity pre/post switch, retention >=75% up to 12 months, and no new safety signals; switch acceptance varied (51.6–99%).

Observational data provide reassurance on biosimilarity in practice.

GVHD evidence: Evidence for GVHD is mixed: some small studies report improved complete response rates and short‑term survival when etanercept was added to steroids in acute GVHD (n=61), but guideline statements note insufficient evidence to recommend etanercept for chronic GVHD; NCCN provides category 2A recommendation in specific contexts.

Heterogeneous evidence base for GVHD.

Selected off‑label/rare conditions: Small case series/reports suggest possible benefit for conditions such as neurocysticercosis (case series n=16 with steroid‑sparing effects), knee OA via intra‑articular injection (small uncontrolled studies), keloids (small RCT), and PG (small retrospective series), whereas LCH had a small phase II trial (n=5) with no responses.

Evidence quality varies and larger RCTs are often lacking.

Psoriasis and Psoriatic Arthritis (adults and pediatrics)

Covered when supported by FDA approval and guideline‑based prior therapy requirements.

Psoriasis/PsA coverage logic: Use for adult chronic plaque psoriasis and psoriatic arthritis is supported by FDA approval and Phase III trial data; pediatric plaque psoriasis (4–17 years) and juvenile psoriatic arthritis (>=2 years) have FDA approvals based on pediatric trials and PK data.PASI‑75 and pediatric trial endpoints as per studies

NICE recommends etanercept for severe adult plaque psoriasis only after failure of standard systemic therapies and to discontinue if inadequate response at 12 weeks.

Pediatric efficacy: Pediatric trial (Paller et al.) showed PASI‑75 at week 12 in 57% for etanercept vs 11% placebo; pediatric dosing guidance (0.8 mg/kg weekly to max 50 mg) applies.PASI‑75 at week 12: 57%

Supports pediatric psoriasis approval and continuation decisions.

Langerhans Cell Histiocytosis (LCH)

Not routinely covered based on available evidence.

LCH evidence and coverage stance: A phase‑II trial in refractory/relapsed Langerhans cell histiocytosis (n=5) showed no clinical responses and was stopped early; evidence is insufficient to support routine coverage.lack of response in small trial

Different dosing/regimens were not adequately evaluated; not medically necessary outside trials.

Neurocysticercosis (NCC)

Experimental/adjunctive use may be considered in refractory inflammatory disease but randomized trial evidence is lacking.

NCC evidence summary: Case series (n=16) reported clinical improvement and steroid‑sparing effects with etanercept for extra‑parenchymal NCC and recurrent perilesional edema; randomized controlled trials are lacking.case‑series level evidence

Consider investigational pending RCTs; monitor risks including infection reactivation and cost.

Pyoderma Gangrenosum (PG)

Limited supportive evidence from small series.

Pyoderma gangrenosum evidence: A small retrospective series (n=7) reported healing or marked reduction in refractory PG ulcers with etanercept (25–50 mg twice weekly); small sample size and retrospective design limit conclusions.case‑series improvements

Other TNF inhibitors (e.g., adalimumab) may be favored by experts; further studies needed.

Radicular pain / Sciatica (epidural or transforaminal use)

Mixed and insufficient evidence for routine coverage of epidural/transforaminal or intradiscal etanercept for radicular pain; considered investigational.

Radicular pain evidence summary: Small RCTs and dose‑response trials reported mixed results: some studies showed short‑term pain relief after epidural/transforaminal etanercept, others found no benefit or steroids superior; UpToDate states insufficient evidence to recommend epidural etanercept.small RCTs with conflicting outcomes

Epidural/transforaminal/intradiscal routes should be considered investigational pending larger confirmatory trials.

Rheumatoid Arthritis (RA)

Guideline‑directed use consistent with ACR recommendations.

RA guideline summary: ACR guidelines recommend initial DMARD monotherapy (methotrexate preferred) for low/moderate disease; TNF inhibitors, including etanercept, are recommended in combination with methotrexate or as subsequent therapy for moderate to high disease activity not controlled with conventional DMARDs.ACR disease activity criteria per guidelines

Use consistent with ACR guidance for sequencing and escalation.

Other conditions (SAPHO, Sarcoidosis)

Very limited evidence; typically not routine—case‑by‑case consideration only.

SAPHO and sarcoidosis evidence: Small case reports/series suggest possible benefit in SAPHO; sarcoidosis evidence is limited with infliximab/adalimumab more commonly used and etanercept not widely effective—evidence insufficient for routine coverage.case reports/series

Consider referral to specialty review for complex cases.

Evidence summaries by indication

Pooled evidence summaries and authors' conclusions across multiple off‑label and investigational uses.

Sciatica / lumbar radiculopathy: Multiple small studies (pilot, dose‑response, RCTs) report mixed findings—some report clinically significant short‑term improvements with transforaminal/epidural etanercept while others show no benefit; authors call for larger randomized trials.study sizes vary (pilot N=10; RCTs N=24, N=49)

Evidence is heterogeneous and insufficient for routine adoption.

SJS/TEN: Case reports and small series indicate etanercept may halt progression in some SJS/TEN patients; NCCN includes etanercept as a category 2A option in certain contexts but evidence is limited and largely observational.case reports/series; guideline category 2A noted

Documentation of severity and rationale required for consideration.

Post‑stroke / TBI (peri‑spinal etanercept): Large open‑label case series (N=629) report improvements across multiple domains, but evidence is Class IV with high risk of bias; AAN concluded insufficient evidence to support routine use and cautioned about adverse outcomes and cost.case series level evidence

Consider experimental status without RCT confirmation.

Transplantation‑related lung injury after HSCT: Small retrospective series (N=17) reported low survival and notable new infection rates after etanercept; caution advised and careful risk/benefit assessment recommended.small retrospective cohort

Use only after specialist consultation and documentation.

Uveitis: Systematic reviews and guideline summaries find infliximab and adalimumab more effective for many ocular inflammatory disorders; etanercept’s role is uncertain and not widely supported by controlled trials.systematic review evidence

Prefer other TNF inhibitors for uveitis where evidence supports them.

Wound healing / PG: Preliminary studies and case reports suggest potential benefit of TNF‑alpha antagonists including etanercept for wound healing and PG; further investigation warranted.preliminary/case report level

Evidence insufficient for broad coverage beyond refractory cases.

Concomitant administration of etanercept with any other biologic (for example, abatacept, adalimumab, anakinra, infliximab, rilonacept, tocilizumab) or with a targeted synthetic agent (for example, tofacitinib) for the same indication is considered experimental and investigational because effectiveness and safety of combined biologic/targeted‑synthetic regimens have not been established.

There is insufficient reliable evidence to support use of etanercept for discoid lupus erythematosus; systematic reviews and trials identify topical corticosteroids, hydroxychloroquine, and acitretin as better‑studied options. Requests for etanercept for discoid lupus should therefore be considered experimental/investigational and alternative, guideline‑supported therapies should be used or documented in the clinical rationale.

Available clinical guidance and reviews do not identify etanercept as a therapeutic option for dyshidrotic (acute palmoplantar) eczema. Because the literature provides no supportive recommendation and efficacy has not been demonstrated, etanercept use for dyshidrotic eczema is considered experimental/investigational.

Epidural, intrathecal, transforaminal or other off‑label spinal routes of etanercept administration for radicular pain (including lumbar disc herniation/sciatica) and the use of etanercept for Langerhans cell histiocytosis (LCH) are considered investigational given conflicting or negative trial results and limited case series. The phase‑II LCH study (n=5) showed no responses and epidural/transforaminal spinal studies provide mixed, inconclusive findings; therefore these indications/routes are not supported for routine coverage.

Evidence supporting etanercept for chronic post‑stroke disability is inadequate. Case series report open‑label improvements, but the American Academy of Neurology concluded the available evidence is insufficient to support or refute benefit (Level U), and randomized controlled data are lacking.

No exclusions are listed in this portion of the document.

The policy’s Experimental and Investigational section enumerates numerous indications and off‑label uses for which etanercept is considered not medically established, including neurologic (stroke, traumatic brain injury, peri‑spinal/targeted spinal injections), dermatologic (dyshidrotic eczema, granuloma annulare, discoid lupus), infectious/inflammatory (neurocysticercosis, LCH), pulmonary (transplantation‑related lung injury), and others. These listed indications are considered experimental/investigational and are excluded from routine coverage pending more robust evidence.

Peri‑spinal or targeted subcutaneous administration of etanercept for chronic discogenic back or neck pain (including peri‑spinal/transforaminal epidural injections for sciatica) is supported primarily by uncontrolled case series and small randomized or pilot studies with mixed results. Because the evidence is limited, heterogeneous, and at risk of bias, these routes and indications are considered not established for routine use and remain experimental/investigational.

A small phase II trial of etanercept in relapsed or refractory Langerhans cell histiocytosis enrolled 5 patients and demonstrated no clinical responses; the study was stopped early for lack of efficacy. This small negative trial does not support etanercept efficacy for LCH.

Because the only clinical trial evidence in LCH is a small phase II study with no responses (n=5), etanercept use in LCH is not supported by adequate evidence and is considered non‑routine; such use should be limited to clinical trials.

Reiterating prior conclusions, the AAN review and available case‑series literature indicate that evidence is insufficient to support etanercept for post‑stroke disability (AAN Level U). In the absence of randomized controlled evidence, this indication is considered unsupported for routine coverage.

Coding and Dosing Information

Covered CPT / HCPCS CodesmixedCovered

20600-20611	Arthrocentesis, aspiration and/or injection
71045-71048	Radiologic examination, chest
85651	Sedimentation rate, erythrocyte; non-automated
85652	Sedimentation rate, erythrocyte; automated
86140	C-reactive protein
86141	C-reactive protein; high sensitivity (hsCRP)
86200	Cyclic citrullinated peptide (CCP), antibody
86430	Rheumatoid factor; qualitative
86431	Rheumatoid factor; quantitative
86480	Tuberculosis test, cell mediated immunity antigen response measurement; gamma interferon

1–10 of 14

1/2

Covered ICD-10 Codes (if selection criteria met)ICD-10Covered

D89.810-D89.813	Graft-versus-host disease
D89.9	Disorder involving the immune mechanism, unspecified [immune checkpoint inhibitor-related toxicity]
L40.0-L40.4	Psoriasis [age 4 and older]
L40.8-L40.9	Psoriasis
L40.50-L40.59	Arthropathic psoriasis [from age 2 years to age 18 and older]
L73.2	Hidradenitis suppurativa
M00.00-M01.x9	Arthropathy associated with infections
M02.30-M02.9	Reiter's disease and other reactive arthropathies
M05.00-M06.9	Rheumatoid arthritis [age 18 and older]
M08.00-M08.9A	Juvenile arthritis [age 2 and older]

1–10 of 13

1/2

ICD-10 Codes Not Covered for Indications ListedICD-10Not Covered

B69.0	Cysticercosis of central nervous system
C96.5	Multifocal and unisystemic Langerhans-cell histiocytosis
C96.6	Unifocal Langerhans-cell histiocytosis
L92.0	Granuloma annulare
M19.041-M19.049	Primary osteoarthritis, hand
M19.141-M19.149	Post-traumatic osteoarthritis, hand
M19.241-M19.249	Secondary osteoarthritis, hand

No codes listed

inv-28: Pediatric weight-based dosing — 0.8 mg/kg weekly, max 50 mg/week for children <63 kg.

Pediatric dosingChildren <63 kg: 0.8 mg/kg weekly, max 50 mg/week

Provider Actions, Prior Authorization and Documentation

Prior Authorization

Prior Authorization Required and Safety Screening

Prior authorization is required for Enbrel (etanercept) and biosimilars. Requests must justify therapy for the specific clinical indication and include pre-initiation safety screening, including documentation of a negative TB test (PPD, IGRA, or chest x-ray) within 6 months prior to initiation for biologic-naive patients; if TB screening is positive, confirm no active disease and document latent TB treatment before starting therapy.

Prior authorization should align with FDA prescribing information (PI) and insurer standards.
For biosimilars, provide evidence of clinical equivalence or rationale for biosimilar selection (trial data, real-world evidence, immunogenicity/safety data).
Pediatric requests should include pediatric efficacy/safety data and relevant PK/extension-study references.

Documentation Required

Clinical Rationale and Required Documentation

Prescribers must indicate the clinical rationale for etanercept use and document prior treatments tried and failed when applicable (e.g., methotrexate or other conventional systemic agents for RA, PsA, PsO, JIA). Documentation must include prescriber specialty or consultation appropriate to the indication and evidence of TB screening and management.

Document indication, disease severity measures (e.g., DAS28, PASI, BSA, CRP/ESR), prior therapy duration and reasons for discontinuation (inefficacy, intolerance, contraindication).
Prescriber specialties required by indication: rheumatologist, dermatologist, oncologist/hematologist as specified in policy.
Continuation requests must meet all initial selection criteria and show ongoing positive clinical response.

Prior Authorization

FDA‑Approved Indications and Prior Therapy Requirements

FDA‑approved indications and prior therapy history must be documented when seeking coverage (e.g., RA, pJIA ≥2 years, PsA, AS, moderate‑to‑severe plaque psoriasis ≥4 years, JPsA ≥2 years). When prior therapy is required by the policy or guidelines (for example, inadequate response to an adequate trial of methotrexate for RA or two NSAIDs for axial spondyloarthritis), provide treatment dates, doses, and objective measures of inadequate response.

For psoriasis: document BSA or PASI, prior phototherapy or systemic agents, and rationale if systemic agents are contraindicated (see Appendix A).
For axial spondyloarthritis: document trials of ≥2 NSAIDs or contraindications; comparative evidence (etanercept vs sulfasalazine) may support step decisions.
Pediatric approvals (PsO, pJIA, JPsA) require pediatric study data and PK justification where applicable.

Denial Risk

Non‑Standard Indications, Limited Evidence, and Required Justification

Some uses (e.g., peri‑spinal administration for post‑stroke/TBI dysfunction, epidural/intradiscal/radicular injections for radicular pain or chronic low back pain) have insufficient or limited evidence. Requests for these indications should include supporting clinical data and explicit acknowledgement of limited evidence and potential for adverse outcomes; such requests may be denied if not supported by robust evidence and alignment with PI.

Post‑stroke/TBI: existing case series and open‑label reports are low quality; cite referenced trials or registries and discuss risks/costs.
Radicular pain/epidural use: state that UpToDate and randomized trials do not support routine epidural etanercept for lumbosacral radiculopathy.
Sciatica/LDH trial submissions should include dosing regimens, route (transforaminal/epidural), outcome measures (ODI, VAS), follow-up durations, and safety data.

Denial Risk

Authorization Risks, Denials, and Administrative Notes

Certain clinical scenarios and administrative gaps may lead to denial of authorization. Common denial risks include missing or inadequate documentation of prior therapies, absent or outdated TB screening/treatment documentation, and requests that deviate from FDA PI without adequate justification. Note that detailed prior authorization procedures and operational PA rules may be located in other sections of the full policy.

Requests may be denied if negative TB testing within the required timeframe is not documented or if latent TB was not treated prior to initiation.
Deviations from FDA labeling (dose, route, indication) require explicit rationale; lack of alignment with PI may result in denial.
Policy history, related administrative rules, and specific PA workflows are documented elsewhere in the complete policy.

Background and Evidence Overview

Etanercept (Enbrel) is a recombinant dimeric fusion protein that binds tumor necrosis factor‑alpha (TNF‑α) and prevents its interaction with TNF receptors. As a TNF blocker, etanercept reduces TNF‑mediated inflammation associated with conditions such as rheumatoid arthritis, psoriatic arthritis and plaque psoriasis. The agent carries labeled warnings for serious infections (including tuberculosis) and malignancy, and appropriate screening and monitoring are required prior to and during therapy.

Evidence summaries by indication and biosimilar (cross-reference)

Background evidence and biosimilar summaries are provided here for cross‑reference and context.

Biosimilar approvals and trials (context): FDA approval of Erelzi (etanercept‑szzs) and randomized phase‑III trial data (LBEC0101) plus real‑world SB4/Benepali registry data support biosimilarity and inform substitution decisions.

See biosimilar trial and real‑world summaries for details on equivalence, AEs, and retention rates.

Selected off‑label evidence (context): Summaries of small RCTs, case series and observational reports for indications such as radicular pain, SJS/TEN, NCC, GVHD, LCH, knee OA, and wound healing provide context on limited and heterogeneous evidence across these uses.

Policy uses these summaries to support investigational or not medically necessary conclusions where appropriate.

Evidence summaries in the policy present indication‑specific conclusions and authors’ interpretations: phase‑III trials and pediatric studies support etanercept efficacy in plaque psoriasis and psoriatic arthritis (including pediatric approvals), biosimilar trials show comparable efficacy and safety, while for many off‑label uses (for example, peri‑spinal administration for chronic pain, LCH, post‑stroke disability) the data are limited to small trials, case series, or conflicting RCTs. Authors consistently call for larger, well‑designed randomized controlled trials before routine coverage can be recommended for these off‑label indications.

Definitions and Key Terms

Etanercept (Enbrel) — definition

Drug classTumor necrosis factor (TNF) blocker — recombinant soluble TNF receptor-Fc fusion protein

Molecular descriptionDimeric fusion protein consisting of the extracellular ligand‑binding portion of the human 75 kDa (p75) TNF receptor linked to the Fc portion of human IgG1

Primary actionBinds TNF and blocks its interaction with cell surface TNF receptors, reducing inflammation

Prescriber specialty requirement

Prescriber requirement — rheumatologic indicationsMust be prescribed by or in consultation with a rheumatologist for RA, articular JIA, ankylosing spondylitis, non-radiographic axial spondyloarthritis, reactive arthritis, and Behcet’s disease

Prescriber requirement — psoriatic arthritis / hidradenitis suppurativaMust be prescribed by or in consultation with a rheumatologist or dermatologist for psoriatic arthritis and hidradenitis suppurativa

Prescriber requirement — plaque psoriasisMust be prescribed by or in consultation with a dermatologist for plaque psoriasis

Prescriber requirement — GVHD and ICI toxicitiesGraft-versus-host disease: oncologist or hematologist; immune checkpoint inhibitor-related toxicity or inflammatory arthritis: oncologist, hematologist, or rheumatologist/dermatologist as specified

Etanercept — molecular description (p75 TNF receptor linked to IgG1 Fc)

Molecular compositionExtracellular portion of the human p75 TNF receptor linked to the Fc portion of human IgG1 (p75 TNF receptor–IgG1 Fc fusion)

ClassificationRecombinant soluble TNF receptor-Fc fusion protein (TNFR:Fc)

MechanismBinds and neutralizes TNF, preventing interaction with cell-surface TNF receptors

Black‑box warnings and labeled precautions

Black‑box infections warningIncreased risk of serious infections (including tuberculosis, bacterial sepsis, invasive fungal infections and opportunistic pathogens); discontinue if serious infection develops; test for latent TB and treat prior to initiation

Malignancy riskReported cases of lymphoma and other malignancies, including fatal cases, in children and adolescents treated with TNF blockers

Other labeled precautionsDemyelinating disease onset/exacerbation, worsening/new congestive heart failure, hepatitis B reactivation, hematologic abnormalities (pancytopenia), anaphylaxis/serious allergic reactions, lupus-like syndrome/autoimmune hepatitis

Etanercept biosimilar approved by FDA — Erelzi (etanercept-szzs)

Biosimilar nameErelzi (etanercept-szzs)

Regulatory statusApproved by the U.S. Food and Drug Administration (FDA) on August 30, 2016

IndicationsApproved for multiple inflammatory diseases including ankylosing spondylitis, psoriatic arthritis (including with MTX), chronic moderate-to-severe plaque psoriasis (adults), polyarticular JIA (≥2 years), and moderate-to-severe RA

Etanercept biosimilar with European marketing authorization — SB4 (Benepali)

Biosimilar nameSB4 (Benepali)

Marketing authorization contextSB4 (Benepali) has European marketing authorization and has been compared with originator etanercept in real-world cohorts showing similar safety and efficacy at 6 months

Real-world evidenceNational registry and pooled observational data reported no significant differences in disease activity or adverse events compared with originator ETN

Neurocysticercosis (NCC) — definition and clinical context

DefinitionNeurocysticercosis (NCC) is inflammatory disease caused by host immune responses to Taenia solium cysts, with manifestations driven by inflammation of drug-damaged or degenerating cysts

Clinical contextComplicated NCC often requires prolonged high-dose corticosteroids; etanercept has been explored as a steroid-sparing or adjunctive therapy in case series

Evidence levelCase series (n=16) reported clinical improvement and steroid-sparing effects, but randomized controlled trials are lacking

PASI-75 — definition

PASI-75 definitionA 75% or greater improvement from baseline in the Psoriasis Area and Severity Index (PASI), a primary efficacy endpoint in psoriasis trials

Clinical useCommon primary endpoint in etanercept psoriasis trials and pediatric studies (e.g., used to define treatment response at week 12)

Example trial resultAdult trials reported ~46% achieving PASI-75 at 3 months; pediatric trial showed 57% vs 11% for placebo at week 12

SJS/TEN — definition and classification

Definition and classificationStevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are delayed-type drug hypersensitivity reactions classified by skin detachment: SJS <10% BSA, SJS/TEN overlap 10–30% BSA, TEN >30% BSA

DiagnosisBased on clinical assessment with supporting histopathology; severity scoring via SCORTEN is used for prognosis

Clinical featuresProdrome (malaise, fever) followed by painful cutaneous and mucous membrane lesions with potential ocular, oral, and genital involvement

Transforaminal epidural etanercept — definition

Administration routeTransforaminal epidural etanercept refers to epidural administration of etanercept via transforaminal injections into the neural foramina for lumbar radiculopathy

Trial regimensClinical trials used regimens such as two transforaminal injections 2 weeks apart at various mg doses with follow-up up to 26 weeks

Evidence summarySmall randomized and dose-response trials reported mixed results; insufficient evidence to recommend routine use

Etanercept (ENBREL) — prescribing information summary

Prescribing summaryEtanercept (ENBREL) is a recombinant soluble TNF receptor-Fc fusion protein indicated for multiple inflammatory conditions per manufacturer prescribing information; dosing varies by indication and age/weight

Key dosing examplesAdults with RA/AS/PsA: 50 mg once weekly; PsO adults: 50 mg twice weekly (starting) then 50 mg once weekly; pediatric weight-based dosing: 0.8 mg/kg weekly to max 50 mg for <63 kg

Safety highlightsBlack-box warnings for serious infections including TB and for malignancies; monitor for infections and test/treat latent TB prior to initiation

Articular juvenile idiopathic arthritis (JIA) — definition and Appendix B reference

Definition — articular JIAArticular juvenile idiopathic arthritis (JIA) is a subtype of juvenile idiopathic arthritis affecting joints; risk factors relevant to management are listed in Appendix B

Appendix referenceAppendix B of the policy lists risk factors for articular JIA to inform treatment decisions

Age applicabilityPolyarticular JIA/juvenile psoriatic arthritis indications for etanercept apply to patients 2 years of age and older per labeling

Policy Revision History

2024-02-15Last reviewLatest

Policy last reviewed on 02/15/2024; content reviewed and administrative details updated.

1999-02-10Effective date

Policy originally became effective on 02/10/1999.

2024-10-24Next scheduled review

Next policy review scheduled for 10/24/2024.